论文部分内容阅读
氨噻肟头孢菌素(Cefotaxime,HR756)是一种新的第三代头孢菌素,它对许多革兰氏阳性及阴性细菌,特别是肠杆菌科细菌,包括对多种抗生素耐药的菌株均呈现极高的抗菌活性,对β-内酰胺酶(包括青霉素酶及头孢菌素酶)具有高度稳定性,仅能被普通变形杆菌、绿脓杆菌、脆弱类杆菌中少数细菌产生的肟型头孢菌素酶(CX_(ase))水解。 国产氨噻肟头孢菌素已由四川抗菌素工业研究所试制成功,并与东北制药总厂、四川长征制药厂联合研制成供临床使用的样品。本文报告重庆医学院用国产 HR756对重庆地区临床分离到的常见致病菌的体外抗菌作用研究结果,并与德意志联邦共和国样品进行比较。
Cefotaxime (HR756) is a new third generation cephalosporin that is effective against many Gram-positive and -negative bacteria, especially Enterobacteriaceae, including strains resistant to multiple antibiotics All showed a very high antibacterial activity of β-lactamase (including penicillinase and cephalosporinase) has a high degree of stability, only by Proteus, Pseudomonas aeruginosa, Bacteroides fragilis bacteria produced by the type of oxime Cephalosporinase (CX ase) hydrolysis. Domestic cefotaxime has been trial-produced by Sichuan Institute of Antibiotics, and has been jointly developed with Northeast Pharmaceutical Factory and Sichuan Changzheng Pharmaceutical Factory for clinical use. This article reports the results of in vitro antibacterial activity of domestic HR756 against common pathogens isolated in Chongqing Medical College by Chongqing Medical College and compares them with the samples of the Federal Republic of Germany.